<SEC-DOCUMENT>0001564590-19-002299.txt : 20190207
<SEC-HEADER>0001564590-19-002299.hdr.sgml : 20190207
<ACCEPTANCE-DATETIME>20190207163431
ACCESSION NUMBER:		0001564590-19-002299
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190207
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190207
DATE AS OF CHANGE:		20190207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Orthofix Medical Inc.
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		19575588

	BUSINESS ADDRESS:	
		STREET 1:		3451 PLANO PARKWAY
		CITY:			LEWISVILLE
		STATE:			TX
		ZIP:			75056
		BUSINESS PHONE:		214-937-2000

	MAIL ADDRESS:	
		STREET 1:		3451 PLANO PARKWAY
		CITY:			LEWISVILLE
		STATE:			TX
		ZIP:			75056

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOFIX INTERNATIONAL N V
		DATE OF NAME CHANGE:	19970708
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ofix-8k_20190207.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ofix-8k_20190207.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): February 7, 2019</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">ORTHOFIX MEDICAL INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">0-19961</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">98-1340767</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">of incorporation) </p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">File Number) </p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Identification No.) </p></td>
</tr>
<tr>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">3451 Plano Parkway</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Lewisville, Texas</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">75056</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (214) 937-2000</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fis_financial_statements_and_exhibits"></a>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="font-style:italic;">see</font> General Instruction A.2. below):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.01 </font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="text-decoration:underline;">Regulation&#160;FD Disclosure.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#252525;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 7, 2019, Orthofix Medical Inc. (the &#8220;Company&#8221;) issued a press release regarding U.S. Food and Drug Administration approval of the Company&#8217;s M6-C&#8482; artificial cervical disc. A copy of that press release is furnished herewith as Exhibit 99.1 and attached hereto.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#252525;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information furnished under this Item 7.01 (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;Background-color:#FFFFFF;">Financial Statements and Exhibits.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#252525;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Exhibits</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#252525;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1<font style="margin-left:36pt;"></font><a href="ofix-ex991_6.htm"><font style="text-decoration:underline;color:#000000;">Press Release, dated February 7, 2019.</font></a></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Medical Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: </p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kimberley Elting </p></td>
</tr>
<tr>
<td valign="top"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kimberley Elting</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal and Administrative Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 7, 2019</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ofix-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ofix-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:545.4pt;;">
<tr>
<td style="width:205.8pt;"></td>
<td style="width:132.15pt;"></td>
<td style="width:94.95pt;"></td>
<td style="width:27.45pt;"></td>
<td style="width:85.05pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpn2hb1ofmxq000001.jpg" title="" alt="" style="width:258px;height:40px;"></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Medical Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3451 Plano Parkway</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lewisville, TX 75056 USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214 937 2000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix.com</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#004A97;font-size:36pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">News Release</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONTACT:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Mark Quick</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denise Landry</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Investor Relations</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Tel&nbsp;&nbsp;&nbsp;&nbsp;214 937 2924</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel&nbsp;&nbsp; 214 937 2529</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; <font style="text-decoration:underline;">markquick@orthofix.com</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">deniselandry@orthofix.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Announces FDA Approval of the M6-C Artificial Cervical Disc to Treat Patients with Cervical Disc Degeneration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Only <font style="color:#000000;">Artificial Cervical Disc that Mimics the Anatomic Structure of a Natural Disc</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEWISVILLE, TX. &#8211; February 7, 2019 &#8211; Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced U.S. Food and Drug Administration (FDA) approval of the M6-C<sup style="font-size:85%; vertical-align:top">&#8482;</sup> artificial cervical disc for patients suffering from cervical disc degeneration. The M6-C artificial cervical disc was developed by Spinal Kinetics, a company acquired by Orthofix in April 2018.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;With the approval of the M6-C artificial cervical disc, Orthofix now has the industry&#8217;s most comprehensive portfolio of cervical spine products to best serve our surgeon customers and patients,&#8221;&nbsp;&nbsp;said Orthofix President and Chief Executive Officer, Brad Mason. &#8220;In addition to a full line of anterior, posterior and interbody fusion cervical implants, we offer the CervicalStim<sup style="font-size:85%; vertical-align:top">&#8482;</sup> device, the only FDA-approved cervical bone growth stimulation therapy, and the Trinity ELITE<sup style="font-size:85%; vertical-align:top"></sup><font style="font-size:10pt;font-family:'Times New Roman'">&#210;</font> allograft, a market-leading allograft developed in partnership with MTF Biologics. The launch of the M6-C artificial cervical disc in the U.S. will complement this existing spine portfolio and represents a significant milestone in the execution of our strategy to accelerate topline growth.&#8221;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The M6-C artificial cervical disc is a next-generation artificial disc developed to replace an intervertebral disc damaged by cervical disc degeneration. Designed to restore physiologic motion to the spine, the M6-C disc is indicated as an alternative to cervical fusion. The M6-C artificial cervical disc preserves motion by restoring biomechanical function at the treated level after native disc removal and potentially reduces subsequent degeneration of adjacent vertebral segments. The M6-C device is the only artificial cervical disc that mimics the anatomic structure of a natural disc by incorporating an artificial visco-elastic <font style="color:#000000;">nucleus and fiber annulus into its design. Like a natural disc, this unique construct allows for shock absorption at the implanted level, as well as provides a controlled range of motion when the spine transitions in its combined complex movements. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-market approval was based on clinical data from a U.S. Investigational Device Exemption (IDE) study that evaluated the safety and effectiveness of the M6-C artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of symptomatic cervical radiculopathy with or without cord compression.<font style="font-family:Times New Roman;color:#000000;"> </font>Patients in the study presented with degenerative cervical radiculopathy requiring surgical intervention, and confirmed clinically and radiographically at one vertebral level from C3 to C7. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study results at 24 months include the following clinical patient outcomes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;color:#000000;">90.5 percent of patients who received the M6-C disc demonstrated a meaningful clinical improvement in the Neck Disability Index.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">A meaningful clinical improvement in arm pain score was seen in 91.2 percent</font><font style="font-family:Arial;letter-spacing:-0.3pt;"> of the </font><font style="font-family:Arial;">M6-C</font><font style="font-family:Arial;letter-spacing:-0.3pt;"> disc </font><font style="font-family:Arial;">patients</font><font style="font-family:Arial;letter-spacing:-0.25pt;"> </font><font style="font-family:Arial;">compared</font><font style="font-family:Arial;letter-spacing:-0.3pt;"> </font><font style="font-family:Arial;">to</font><font style="font-family:Arial;letter-spacing:-0.3pt;"> </font><font style="font-family:Arial;">77.9 percent in ACDF patients. In addition, this same meaningful improvement was seen in neck pain scores with 90.5 percent of patients who received the M6-C disc compared to 79.9 percent in patients who underwent the ACDF</font><font style="font-family:Arial;letter-spacing:-0.25pt;"> </font><font style="font-family:Arial;">procedure.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">The M6-C disc preserved range of motion in flexion-extension and lateral bending in the study group.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpn2hb1ofmxq000002.jpg" title="" alt="" style="width:258px;height:40px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Arial;">Prior to surgery, 80.6 percent of the M6-C disc patients and 85.7percent of the ACDF patients were taking some type of pain medication for the treatment of their cervical spine condition. At 24 months, 14.0 percent of the M6-C disc pa</font><font style="font-family:Arial;">tients were still taking some type of pain medication compared to 38.2 percent of the ACDF patients.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Arial;">Of the patients still taking pain medication there was a seven times higher rate of opioid use with the ACDF patients than with patients who received the M6-C disc.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">Additional surgery at the treated level was needed in 4.8 percent of the ACDF patients compared to 1.9 percent of the M6-C disc patients. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prospective, non-randomized, concurrently controlled, multi-center clinical trial was conducted at 23 sites in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Cervical disc degeneration is a common condition that can cause pain in the neck, shoulders, arms and hands and lead to numbness and weakness in the arm or hands. Often this condition is the result of a vertebral disc that has deteriorated or been <font style="color:#000000;">damaged due to the natural aging process or an injury,&#8221; said Dr. Rick Sasso, orthopedic spine surgeon, </font><font style="Background-color:#FFFFFF;">professor and chief of spine surgery at the Indiana University School of Medicine in Indianapolis </font><font style="color:#000000;">and an investigator in the M6-C artificial cervical disc IDE study. &#8220;For many of these patients, the M6-C artificial cervical disc will give us the ability </font>to replace the patient&#8217;s damaged disc with one that closely mimics their natural disc, enabling them to regain motion and return to their normal activities.&#8221; </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix expects to release the M6-C artificial cervical disc in 2019 through a controlled, limited market launch in the U.S accompanied by an extensive training and education curriculum for surgeons. The M6-C artificial cervical disc received CE Mark approval for distribution in the European Union and other international geographies in 2006 and there have been more than 45,000 implants of the M6-C artificial cervical disc outside of the U.S. to date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Conference Call</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will conduct a conference call to discuss the FDA approval of the M6-C artificial cervical disc along with its fourth quarter and fiscal 2018 financial results on Monday, February 25 at 3:30 p.m. Central time (4:30 p.m. Eastern time). Interested parties may access the conference call by dialing (844) 809-1992 in the U.S. and (612) 979-9886 outside the U.S., and referencing the conference ID 7446347. A replay of the call will be available for two weeks by dialing (855) 859-2056 in the U.S. and (404) 537-3406 outside the U.S., and entering the conference ID 7446347. A webcast of the conference call may be accessed by going to the Company's website<font style="color:#0072C6;"> www.orthofix.com</font> by clicking on the Investors link and then the Events and Presentations page. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About Orthofix</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Medical Inc.&#160;is a global medical device company focused on musculoskeletal products and therapies. The Company&#8217;s mission is to improve patients' lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in&#160;Lewisville,&#160;Texas, Orthofix&#8217;s spine and orthopedic extremities products are distributed in more than seventy countries via the Company's sales representatives and distributors. For more information, please visit&#160;<font style="color:#0072C6;">www.orthofix.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (&#8220;the Exchange Act&#8221;), and Section 27A of the Securities Act of 1933, as amended, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. These forward-looking statements involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Orthofix&#8217;s results <font style="Background-color:#FFFFFF;">to differ materially from historical results or those expressed or implied by such forward-looking statements. </font>Therefore, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or other comparable terminology. <font style="Background-color:#FFFFFF;">The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that spine surgeons may be slow to adopt the M6-C artificial cervical disc; the risk that future patient studies or clinical experience and data may indicate that treatment with the M6-C artificial cervical disc does not improve patient outcomes, or otherwise call into question the benefits of its use to patients, hospitals and surgeons; the risk that the product may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that insurance payers may refuse to reimburse healthcare providers for the use of our products; and other risks and uncertainties more fully described in Orthofix&#8217;s periodic filings with the Securities and Exchange Commission, including under the heading &#8220;Risk Factors&#8221;&nbsp;&nbsp;in our annual and quarterly reports.</font> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpn2hb1ofmxq000002.jpg" title="" alt="" style="width:258px;height:40px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We u</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ndertake no obligation to further update any such statement to reflect new information, the occurrence of future events or circumstances or otherwise.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gpn2hb1ofmxq000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpn2hb1ofmxq000002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[@ .061O8F4 9      !_^$+C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
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M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@
M8P)Y P$1  (1 0,1 ?_$ !\  0 # 0$! 0$  P         )"@L(!@<%! $"
M __$ % 0   & @$" P(("@0,! <   $" P0%!@ '"!()$1,*%!4A%K=8>-@Y
M&B(C%U=WEQ@XJ+@QE-;703)")+56MC>(Z!EI43/5F&%2-$0F)Z?_Q  = 0$!
M  (# 0$!            " <)! 4& P$"_\0 /!$  @$# @0% @,%!@<!
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MS3/W\XYR1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & ?_]"_Q@'X=EL];ID#*VJX6&#JE8@FBC^;L=EEF$% P[!+
MP\U[*S$HX:Q\>T3Z@ZE%E"$#Q^$<Y&+BY6=D6<3"QKE[+N2I&$(N<Y/RC&*;
M;]$FSCY>7B8&->S,[*MV<2W'JG.Y)0A%+QE*348KU;2*]G,GO[T:DMYFG\)]
M>2O(*VMEWL4MM>2A+ CIN#?MP%,ZD,BQ1;3^PUVRWP""9XN/.0Q%D7;E,>D:
M/V3\=\_/E8S=]ZE#3<-I26/&4'DS3_>;;A937FKD^<90@^),N^ODEIVGQOX.
MP-,GJ>:FXO(E":Q8-?NI)3O-/R=N#X2C.:X%2ODSR?Y'\H;VM;.2&P[7<K*R
M%5)A$3A?=$+56[D07&/KE.9-X^$K350IBB8K9JD=;X#J&.8>H;$VMM3;&U-/
MCA[8TVS8Q9<Y1^J5QKA6=QMRF_XI.G)47 BS=F[MT[OU&6;NK4[U_+CP49_3
M&VGQZ86DHPMK^&*KS=7Q.;\].>6& , 8 P"6KM@=U'9? F\,ZQ8W$S>N,MFE
M.J[:X!P#AW5W#Y1(KF\ZY*[5(A'6%H!0.Z9=:3.72 4UO+7\ATAAWNMVDTON
M'@3R\:,,?=5J'\J]2BN)<K5ZG&4'RC*CE;?&-8]4)9I[1]XM6[<:A#$RI7,C
M:5V?\VQ6KMM\[UBO",USE"JC=7"5)=,XW^Z#?:=M*E5?8NO;%&VVD72$86*K
MV.(6%:/EX>20*X:.T#&*FJF)B&\#I*%(LBH!DU"$.4Q0UUZCI^;I.=EZ9J6-
M*SGV+CA<A)4<91=&G_V:JFN*;33-E&FZE@ZQ@8>J:9E0O:?D6U.W.+K&49*J
M:_[IT:=4TFFCUV<,YHP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M6L5K?FS=T 6=I>\JQJ+4S1D)&ZH)HN 3N>_:C(^2_(/F)![/Y@$#\:5,WX.
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M12(F55M(+-P47( J !512 X\D/6F=JMF]<-6VD^><L@@H)$Y&/U3H5-D\*
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M1TQOQN+5.7N5400ND>U\LB43L&NKKUV\QZ;8BJJC5F6RQCE5F53I4.P504$
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M-\Q@VV]Y8KB9WOIINX,W:(S%AE&Z:TEN6DQQ@,J_2?%<6=--0ZK=X[\E&-5
MTJZ7<ZEL>GU78-!LD+<:->*[#6ZG6VN2+:7K]GJ]BCF\O S\'*LE%FDC$R\8
M[2<-UTC&3524*8HB X!XG?6]=5\9--;)Y ;OMT?1-4:EJ<I<[Q:9+S3HQL-%
M)=9DVK1N15[*S$DY.FT8,&R:KR0?+HMFZ:BZJ9# 97_=C]31S;Y\7"W4/0-W
MN7%#B3[<^C*[1->S!JSM#8$ DX42:S.W=B5]P6P>U33/Q,YK\2^0@D4E?9EP
MD3)@[4 K3K+*N%55UU5%UUU#K+++',HJLJH83J*JJ'$QU%%#F$3&$1$1'Q'
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M'L;?DM <7Z)-MG MGD0[VHQGG=UD(]8A!72EF^IJM8A9+)'25:N_*7(<#)
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M8)Y]I/V.CZZHCJ)9C5+G78[W.A':W:K)]:!EO.75\3B7H*4"3?[[1SZ^:CQ
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MU9)KHMI39W%I>:KAUC"4SY_KK95.6?1#;\+P.Z5AK4X>=/3_ .2Q4'Q#I\#
M:9. , 8 P"C=ZWO:$5'<<^#&ES+MS3EQW7LW:";8"];M&*UK18RJ+KG.5T7V
M9NX>;73*4#HG\\R1N@Y/).4X&<Q@%B#TJ]7EI_OB\2):.2*HSH]=Y(6B>.8%
MA%")=\:-M4M%4GE(JD PSMO9$_&&3)X''P,)^DA@/.^J.^W7YS?\,W\GG'W
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M>X;GM$3[2"9#L8>1K$!#MG[<JI57!I5IYA#-UTS@0!^J.^W7YS?\,W\GG'W
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M[0]2;2,E([;UA3H@K9/9]?3\QX_G]S5=FS!2:()#.[2R,JZ\PTDV*E) 9Y.
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M(H^T*TPL.R]!.X!]/T"SQ=KAF<XUC>,L3(N8=S(Q*9'*;=TV6.B8P$53,('
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M[4]R\SMSKOOSZKN@9+4<FTN+:7*[!-I>Y;JZ5:4HN4'2JE'$W=WM?A=R]O\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MQC!'7V>,/;C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8!__]._Q@# & , 8 P"(IY[J_ZG</Y_[/\ \</B/_G_
M .TW\<_VF_BW\8;/\6_V-_=O_P"B_P DWLO_ )_NW_\ +/;?;/?O^<>&9EA[
MW_Y5>Z?ZC]E]QP^Q]K['KZ+?7_4NK_5_<5Y=?^GZ>C[?Z3"4_9__ %RQU?TS
M[[[?C]_[OW_M]=SV_P"F=/\ I/MJ<_;_ -1U^Y]S]1+KF&C-HP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gpn2hb1ofmxq000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpn2hb1ofmxq000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I 0,# 2(  A$! Q$!_\0
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00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
